51
|
Zaim R, Tran L, Groen HJM, Uyl-de Groot CA. 'DE NOVO' Quantification of Genotype-Directed Therapy with Afatinib in Metastatic Lung Cancer. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2014; 17:A641. [PMID: 27202295 DOI: 10.1016/j.jval.2014.08.2315] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|
52
|
Fu A, Abunassar J, Le May M, Chong A, Labinaz M, Dick A, Glover C, Froeschl M, Marquis J, Malhotra N, Tran L, Hibbert B, So D. TICAGRELOR VERSUS CLOPIDOGREL AMONG PATIENTS USING TRIPLE THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION: THE CAPITAL ATACC STUDY. Can J Cardiol 2014. [DOI: 10.1016/j.cjca.2014.07.102] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
53
|
Tran L, Krishnan L, Priddy L, Guldberg R. An Effective Alternative to Autogenous Bone Grafts in Critically Sized Defects. J Oral Maxillofac Surg 2014. [DOI: 10.1016/j.joms.2014.06.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
54
|
Tran L, Greenwood-Van Meerveld B. In a non-human primate model, aging disrupts the neural control of intestinal smooth muscle contractility in a region-specific manner. Neurogastroenterol Motil 2014; 26:410-8. [PMID: 24548258 PMCID: PMC4077178 DOI: 10.1111/nmo.12290] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2013] [Accepted: 11/22/2013] [Indexed: 12/15/2022]
Abstract
BACKGROUND Incidences of gastrointestinal (GI) motility disorders increase with age. However, there is a paucity of knowledge about the aging mechanisms leading to GI dysmotility. Motility in the GI tract is a function of smooth muscle contractility, which is modulated in part by the enteric nervous system (ENS). Evidence suggests that aging impairs the ENS, thus we tested the hypothesis that senescence in the GI tract precipitates abnormalities in smooth muscle and neurally mediated contractility in a region-specific manner. METHODS Jejunal and colonic circular muscle strips were isolated from young (4-10 years) and old (18+ years) baboons. Myogenic responses were investigated using potassium chloride (KCl) and carbachol (CCh). Neurally mediated contractile responses were evoked by electrical field stimulation (EFS) and were recorded in the absence and presence of atropine (1 μM) or NG-Nitro-l-arginine methyl ester (l-NAME; 100 μM). KEY RESULTS The myogenic responses to KCl in the jejunum and colon were unaffected by age. In the colon, but not the jejunum, CCh-induced contractile responses were reduced in aged animals. Compared to young baboons, there was enhanced EFS-induced contractility of old baboon jejunal smooth muscle in contrast to the reduced contractility in the colon. The effect of atropine on the EFS response was lower in aged colonic tissue, suggesting reduced participation of acetylcholine. In aged jejunal tissue, higher contractile responses to EFS were found to be due to reduced nitregic inhibition. CONCLUSIONS & INFERENCES These findings provide key evidence for the importance of intestinal smooth muscle and ENS senescence in age-associated GI motility disorders.
Collapse
|
55
|
Tran L, Rieu C, Gaillard R, Krebs MO, Advenier-Iakovlev E. DI-102 Use of pramipexole in resistant depression: analysis of prescriptions over one year in a psychiatry unit. Eur J Hosp Pharm 2014. [DOI: 10.1136/ejhpharm-2013-000436.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
56
|
Tran L, Serrato T, Lacolley P, Bezie Y, Marchais S, Regnault V, Pannier B. 5.3 PLATELET AGGREGATION IS MODULATED BY ARTERIAL STIFFNESS IN END STAGE RENAL DISEASE. Artery Res 2014. [DOI: 10.1016/j.artres.2014.09.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
57
|
Tran L, Lasher BK, Young KA, Keele NB. Depletion of serotonin in the basolateral amygdala elevates glutamate receptors and facilitates fear-potentiated startle. Transl Psychiatry 2013; 3:e298. [PMID: 24002084 PMCID: PMC3784761 DOI: 10.1038/tp.2013.66] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2013] [Revised: 06/23/2013] [Accepted: 07/15/2013] [Indexed: 11/09/2022] Open
Abstract
Our previous experiments demonstrated that systemic depletion of serotonin (5-hydroxytryptamine, 5-HT), similar to levels reported in patients with emotional disorders, enhanced glutamateric activity in the lateral nucleus of the amygdala (LA) and potentiated fear behaviors. However, the effects of isolated depletion of 5-HT in the LA, and the molecular mechanisms underlying enhanced glutamatergic activity are unknown. In the present study, we tested the hypothesis that depletion of 5-HT in the LA induces increased fear behavior, and concomitantly enhances glutamate receptor (GluR) expression. Bilateral infusions of 5,7-dihydroxytryptamine (4 μg per side) into the LA produced a regional reduction of serotonergic fibers, resulting in decreased 5-HT concentrations. The induction of low 5-HT in the LA elevated fear-potentiated startle, with a parallel increase in GluR1 mRNA and GluR1 protein expression. These findings suggest that low 5-HT concentrations in the LA may facilitate fear behavior through enhanced GluR-mediated mechanisms. Moreover, our data support a relationship between 5-HT and glutamate in psychopathologies.
Collapse
|
58
|
Tran L, Chaloner A, Sawalha AH, Greenwood Van-Meerveld B. Importance of epigenetic mechanisms in visceral pain induced by chronic water avoidance stress. Psychoneuroendocrinology 2013; 38:898-906. [PMID: 23084728 DOI: 10.1016/j.psyneuen.2012.09.016] [Citation(s) in RCA: 92] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2012] [Revised: 09/19/2012] [Accepted: 09/20/2012] [Indexed: 12/12/2022]
Abstract
Epigenetic molecular mechanisms, which include DNA methylation and histone deacetylation, are implicated in the dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis. Previously, we demonstrated that repeated water avoidance stress (WAS), a validated model of chronic psychological stress, induces heightened visceral pain behaviors in rodents that resemble irritable bowel syndrome (IBS) sequelae. However, the involvement of epigenetic molecular mechanisms in the pathophysiology of stress-induced visceral pain has not been explored. Our hypothesis is that epigenetic mechanisms within the central nervous system (CNS) are important to chronic stress-induced visceral hypersensitivity. Adult male F-344 rats with intracerebroventricular (i.c.v.) cannulae were exposed to 7 days of repeated WAS. Controls received a SHAM stress. Following the daily 1h stressor, trichostatin A (TSA; 100 ng/ml), a potent histone deacetylase inhibitor, or vehicle (VEH; 0.1% DMSO/saline,) as control was administered via the i.c.v. cannula. Visceral sensitivity was assessed 24h after the final WAS and quantified the visceromotor response (VMR) by recording the number of abdominal contractions in response to graded pressures (20-60 mmHg) of colorectal distensions (CRD). From a separate group of rats that were exposed to repeated WAS or SHAM stress, the amygdala was isolated to assess the methylation status of glucocorticoid receptor (GR) and corticotropin releasing-factor (CRF) genes via bisulfite sequencing and verified by pyrosequencing. GR and CRF gene expression was quantified via qRT-PCR. Stressed rats exhibited visceral hypersensitivity that was significantly attenuated by TSA. Compared to SHAM controls, methylation of the GR gene was increased following WAS while expression of the GR gene was decreased. Methylation of the CRF promoter was decreased with WAS with a concomitant increase in CRF expression. This study demonstrates the involvement of central epigenetic mechanisms in regulating stress-induced visceral hypersensitivity and provides a foundation for exploring the epigenetic mechanisms that may contribute to IBS-like symptomatology.
Collapse
|
59
|
Beaussier H, Coudore F, Bobrie G, Peyrard S, Tran L, Bezie Y, Azizi M, Boutouyrie P. CPC-065 How to Assess Medication Adherence Among Patients with Resistant Hypertension Treated with Two Different Pharmacological Intensification Strategies. Eur J Hosp Pharm 2013. [DOI: 10.1136/ejhpharm-2013-000276.522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
60
|
Tran L, Jardin M, Cherifi M, Bezie Y, Deplanque G. OHP-019 Day-1 Call in an Oncology Day Unit: What Improvements? Eur J Hosp Pharm 2013. [DOI: 10.1136/ejhpharm-2013-000276.393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
61
|
Nguyen N, Passmore J, Pham C, La Q, Nguyen V, Tran L, Luong A, Nguyen L. Drink driving prevention in Ha Nam and Ninh Binh provinces of Viet Nam. Inj Prev 2012. [DOI: 10.1136/injuryprev-2012-040590r.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
62
|
Lynch RM, Tran L, Wu X, Li Y, Lee B, Mascola J. Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01. Retrovirology 2012. [PMCID: PMC3442067 DOI: 10.1186/1742-4690-9-s2-p87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
63
|
Tran L, Huitema ADR, Vogel WV, Beijnen JH, Baars JW. Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion. J Oncol Pharm Pract 2012; 18:417-20. [PMID: 22228555 DOI: 10.1177/1078155211428998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Radioimmunotherapy has emerged as a treatment modality for patients with CD20 positive B-cell non-Hodgkin's lymphoma (NHL). Prior to administration of a therapeutic dose, confirmation of uptake of the radiolabeled compound in tumor locations and calculation of an appropriate dose can be performed using a diagnostic dose and subsequent imaging. We report the case of a 69-year-old male with a relapsed mantle cell lymphoma scheduled for radioimmunotherapy, where diagnostic imaging with 131-I labeled rituximab revealed unexpected new insights with implications for treatment. Persistence of the mantle cell lymphoma in a lymph node in the left arm was demonstrated by an 18-F fluorodeoxyglucose scan. However, a scan after a diagnostic dose of 131-I labeled rituximab did not show any uptake of the tracer, even though subsequent cytological analysis unequivocally confirmed a CD20 positive B-cell population in the lesion. The administration of a therapeutic dose of 131-I labeled rituximab was therefore cancelled. We here discuss the mechanisms that may explain lack of targeting in a proven CD20-positive lymphoma and provide recommendations for further studies.
Collapse
|
64
|
Andrianopoulos N, Tran L, Shardey G, Smith J, Cameron P, Reid C. Application of Funnel Plots and Variable Life Adjusted Displays (VLAD) on Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) Registry. Heart Lung Circ 2012. [DOI: 10.1016/j.hlc.2012.05.672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
65
|
Abstract
AIM To assess the prevalence and type of taste disorders in Aboriginal and non-Aboriginal children matched for age, gender and living in the same general and educational environment. METHODS Taste function was assessed in 432 Aboriginal (n = 166) and non-Aboriginal (n = 266) children aged 8-12 years from six public schools in a rural township using a three-choice taste identification test and a cross-sectional design. RESULTS The prevalence of taste disorders was very high and significantly more common in Aboriginal (20/166; 12.0%) than in non-Aboriginal (21/266; 7.9%) children. Forty-one children had quality-specific disorders, of whom 27 (65.9%) had sweet disorders. Children often had more than one quality disorder. CONCLUSION The prevalence of taste disorders in children was high and exceeded the level (4%) designated by the World Health Organisation as requiring immediate action by health authorities. As the cause of the disorders is unknown, there is a need for a wider investigation of the causes and the consequences.
Collapse
|
66
|
So D, Goncalves S, Roberts J, Stewart A, Al-turbak H, Le May M, Glover C, Marquis J, Dick A, O'Brien E, Froeschl M, Tran L, Szymanska I, Labinaz M. 332 Genetic testing for cyp2c19*2 but not for pon-1 qq carrier status predicts high on-clopidogrel platelet reactivity in patients undergoing percutaneous coronary interventions. Can J Cardiol 2011. [DOI: 10.1016/j.cjca.2011.07.619] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
67
|
Pervin S, Tran A, Tran L, Urman R, Braga M, Chaudhuri G, Singh R. Reduced association of anti-apoptotic protein Mcl-1 with E3 ligase Mule increases the stability of Mcl-1 in breast cancer cells. Br J Cancer 2011; 105:428-37. [PMID: 21730980 PMCID: PMC3172901 DOI: 10.1038/bjc.2011.242] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Background: Mechanisms that increase resistance to apoptosis help promote cellular transformation. Cancer cells have deregulated apoptotic pathways, where increased expression and stability of anti-apoptotic proteins Mcl-1 and Bcl-2 increases resistance to apoptosis. Pathways that increase the stability of proteins in cancer cells remain poorly understood. Methods: Using human mammary epithelial and established breast cancer cell lines, we assessed the mechanisms that increase the stability of anti-apoptotic proteins in breast cancer cells by caspase assay, western blot, small-inhibitory RNA treatment and immunoprecipitation. Results: While breast cancer cells were resistant to de novo inhibition of protein synthesis, a rapid proteosome-mediated degradation of Mcl-1 and Bcl-2 induced apoptosis in mammary epithelial cells. Although Mule, an E3 ligase that targets Mcl-1 for degradation was expressed in mammary epithelial and breast cancer cell lines, rapid increase of polyubiquitinated Mcl-1 and Bcl-2 was detected only in mammary epithelial cells. Only transient formation of the Mule–Mcl-1 complex was detected in breast cancer cells. Downregulation of pERK1/2 in breast cancer cells reduced Mcl-1 levels and increased Mcl-1/Mule complex. Conclusion: Our findings suggest that reduced Mule/Mcl-1 complex has a significant role in increasing the stability of Mcl-1 in breast cancer cells and increased resistance to apoptosis.
Collapse
|
68
|
Jankowski V, Patzak A, Herget-Rosenthal S, Zidek W, Jankowski J, Jankowski V, Toelle M, van der Giet M, Zidek W, Jankowski J, Bae EH, Ma SK, Lee J, Kim SW, Jin K, Kim HJ, Vaziri ND, Osaki K, Suzuki Y, Sugaya T, Nishiyama A, Horikoshi S, Tomino Y, Matthesen SK, Gjoerup PH, Larsen T, Lauridsen TG, Nykjaer KM, Vase H, Pedersen EB, Jin K, Kim YW, Fujimori A, Yuyama H, Takakura K, Tahara A, Koakutsu A, Sanagi M, Sudoh K, Terada Y, Takakura K, Mizukami K, Miura M, Yokoyama K, Amano Y, Furukawa T, Tomura Y, Uchida W, Walkowska A, Kompanowska-Jezierska E, Sadowki J, Ozdemir ZN, Sener G, Ozgur S, Koc M, Suleymanoglu S, Yegen B, Efrati S, Berman S, Abu-Hamad R, Siman-Tov Y, Weissgarten J, Hermida RC, Ayala DE, Mojon A, Chayan L, Dominguez MJ, Fontao MJ, Alonso I, Fernandez JR, Hermida RC, Ayala DE, Mojon A, Fernandez JR, Hermida RC, Ayala DE, Fontao MJ, Mojon A, Chayan L, Dominguez MJ, Fernandez JR, Zanoli L, Alivon M, Estrugo N, Ketthab H, Pruny JF, Yanes S, Bean K, Empana JP, Jouven X, Laude RD, Laurent S, Boutouyrie P, Botticelli I, Quartagno R, Venturini M, Salvioni M, Lanzani C, Simonini M, Delli Carpini S, Zagato L, Manunta P, Blazquez-Medela AM, Garcia-Ortiz L, Gomez-Marcos MA, Recio-Rodriguez JI, Martin-Hinojal M, Rodriguez-Martin C, Castano-Sanchez C, de Cabo-Laso A, Sanchez-Salgado B, Lopez-Novoa JM, Martinez-Salgado C, Villevalde S, Tyukhmenev E, Klimenko A, Kobalava Z, Shin SJ, Oh SW, Rhee MY, Schneider M, Janka R, Raff U, Ritt M, Ott C, Uder M, Schmieder R, Ayala DE, Hermida RC, Golan E, Bernheim J, Podjarny E, Ozturk K, Bulucu F, Gezer M, Kilic S, Steele A, Rene de Cotret P, Hubert M, Leclerc JM, Tran L, Rigal R, Larsen T, Christensen FH, Bech JN, Pedersen EB, Raju B, Nirmala VR, Vijayalakshmi J, Kalaiselvi M, Rekha K, Paiva CE, Leone Aguiar AF, Coelho EB, Irzyniec T, Jez W, Paterno JC, Jara ZP, Barrinha FF, Freire AO, Casarini DE, Teixeira VDPC, Kose E, Can E, Alparslan C, Dogan A, Bal A, Demir BK, Anil M, Anil AB, Yavascan O, Aksu N, Villevalde S, Tyukhmenev E, Klimenko A, Kobalava Z, Irzyniec T, Prusek J, Szypula M, Grun O, Jeken J, Cremers B, Steimle C, Kersting S, Fliser D, Heine G, Hermida RC, Ayala DE, Fontao MJ, Mojon A, Fernandez JR, Pillar R, Lopes MGG, Cuppari L, Carvalho AB, Canziani MEF, Lipkowska K, Blumczynski A, Soltysiak J, Silska M, Poprawska A, Musielak A, Zaniew M, Zachwieja J, Labrador PJ, Gonzalez Castillo PM. Hypertension & hormones. Clin Kidney J 2011. [DOI: 10.1093/ndtplus/4.s2.45] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
69
|
Tran L, Baars JW, de Boer JP, Hoefnagel CA, Beijnen JH, Huitema ADR. The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab. Hum Antibodies 2011; 20:37-40. [PMID: 21558622 DOI: 10.3233/hab20110240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
PURPOSE To report the pharmacokinetics of ¹³¹I-rituximab a patient with a CD20 positive non-Hodgkin Lymphoma who has received ¹³¹I-rituximab as consolidation treatment after remission induction and to evaluate the effect of radioiodination on the biological properties of rituximab. RESULTS The patient was a 65-year-old male with a relapsed CD20 positive follicular non-Hodgkin Lymphoma. After induction therapy the patient was in partial remission. Following administration of a diagnostic dose of 185 MBq ¹³¹I-rituximab, remaining lesions were identified on the wholebody scans. The patient then received a therapeutic dose of 1000 MBq ¹³¹I-rituximab. The uptake by the tumor in the right axilla was 0.17-0.21% of the injected dose. The calculated biological half-life of ¹³¹I-rituximab was 684 hrs. This biological half-life corresponded well with the half-life of unlabeled rituximab which was approximately 720 hrs. DISCUSSION AND CONCLUSION Even though radioiodination of rituximab results in a reduced binding capacity, whole body scans demonstrated localization of ¹³¹I-rituximab in the tumor area. This observation supports the specific targeting of ¹³¹I-rituximab. The half-life of ¹³¹I-rituximab corresponded to the half-life of unlabeled rituximab. Hence, the pharmacokinetics of ¹³¹ I-rituximab was not relevantly affected by the radioiodination process.
Collapse
|
70
|
Tran L, Huitema ADR, van Rijswijk MH, Dinant HJ, Baars JW, Beijnen JH, Vogel WV. CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis. Hum Antibodies 2011; 20:29-35. [PMID: 21558621 DOI: 10.3233/hab20110239] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
INTRODUCTION Visualization of the CD20-antigen expression could provide a tool to localize sites of inflammation and could be of additive value in the diagnosis, and subsequently, in the treatment follow-up of patients with rheumatoid arthritis. In this study, an anti-CD20 monoclonal antibody, rituximab (Mabthera®), was radiolabeled with ¹²⁴Iodine. We report the first results of I¹²⁴-rituximab PET/CT in patients with rheumatoid arthritis. METHODS Eligible patients received 50 MBq ¹²⁴I-rituximab. Wholebody PET/CT imaging was performed at 10 min, 24 h, 48 h and 72-96 h post injection. Images were evaluated primarily on a visual basis and were correlated with disease activity as determined by physical examination and clinical measures. RESULTS Joints with visually detectable targeting of ¹²⁴I-rituximab were observed in 4 out of 5 evaluable patients. Only the images at 24 h and later showed accumulation in joints, indicating that the visualized signal represented active targeting of rituximab to the CD20 antigen. Several images showed CD20 positive B-cell infiltration in joints which were clinically normal, while a few clinically diagnosed arthritis localizations were not visualized. This discrepancy suggests that infiltration of CD20 positive B-cells in synovium is a phenomenon that is at least partially independent of clinical inflammation. The level of uptake in joints was generally low, representing less than 0.5% of the injected dose. CONCLUSION We have shown the feasibility of CD20 antigen imaging using ¹²⁴I-rituximab in patients with rheumatoid arthritis. Further research is needed to elucidate the clinical significance of demonstrated B-cell infiltration in rheumatic joints.
Collapse
MESH Headings
- Antibodies, Monoclonal/immunology
- Antibodies, Monoclonal/pharmacokinetics
- Antibodies, Monoclonal, Murine-Derived/immunology
- Antibodies, Monoclonal, Murine-Derived/pharmacokinetics
- Antigens, CD20/biosynthesis
- Antigens, CD20/immunology
- Antirheumatic Agents/immunology
- Antirheumatic Agents/pharmacokinetics
- Arthritis, Rheumatoid/diagnosis
- Arthritis, Rheumatoid/drug therapy
- Arthritis, Rheumatoid/immunology
- Arthritis, Rheumatoid/pathology
- B-Lymphocytes/immunology
- B-Lymphocytes/metabolism
- B-Lymphocytes/pathology
- Drug Administration Schedule
- Female
- Humans
- Iodine Radioisotopes/adverse effects
- Isotope Labeling/methods
- Male
- Middle Aged
- Positron-Emission Tomography/methods
- Rituximab
- Synovial Membrane/drug effects
- Synovial Membrane/immunology
- Synovial Membrane/metabolism
- Thyroid Gland/drug effects
- Tissue Distribution
- Treatment Outcome
- Whole Body Imaging
Collapse
|
71
|
Tran L, Vogel WV, Sinaasappel M, Muller S, Baars JW, van Rijswijk M, Dinant HJ, Beijnen JH, Huitema ADR. The pharmacokinetics of ¹²⁴I-rituximab in patients with rheumatoid arthritis. Hum Antibodies 2011; 20:7-14. [PMID: 21558619 DOI: 10.3233/hab20110237] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Rheumatoid arthritis is a destructive inflammatory joint disorder. Pre- and mature B-cells, characterized by CD20 antigen expression, play an important role in the inflammatory process. Rituximab, a chimeric monoclonal antibody against the CD20 antigen, has been approved since 2006 for the treatment of patients with rheumatoid arthritis. However, not all patients benefit from this treatment. Persistent activity of the disease has been reported despite treatment with rituximab. Imaging of radiolabeled rituximab can be used to monitor the biodistribution of rituximab, and potentially to predict the efficacy of the treatment. In this study, rituximab was radiolabeled with ¹²⁴Iodine for positron emission tomography (PET) imaging. The aim of this study was to investigate the pharmacokinetics and biodistribution of ¹²⁴I-rituximab in patients with rheumatoid arthritis, to establish the optimal procedure for PET imaging. Eligible patients received 50 MBq ¹²⁴I-rituximab, corresponding to approximately 1.5 mg rituximab. Wholebody PET/CT imaging was performed at 10 min, 24 hrs, and 48 hrs post injection. The total body activity, radioactivity in whole blood, and rituximab serum levels were determined. ¹²⁴I-rituximab has favorable pharmacokinetics for targeting of (pathological) B cells and imaging over several days, but only after pre-treatment with unlabeled rituximab. In addition, protection of the thyroid is recommended to prevent uptake of released ¹²⁴I.
Collapse
MESH Headings
- Antibodies, Monoclonal/immunology
- Antibodies, Monoclonal/pharmacokinetics
- Antibodies, Monoclonal, Murine-Derived/immunology
- Antibodies, Monoclonal, Murine-Derived/pharmacokinetics
- Antigens, CD20/biosynthesis
- Antigens, CD20/immunology
- Antirheumatic Agents/immunology
- Antirheumatic Agents/pharmacokinetics
- Arthritis, Rheumatoid/diagnosis
- Arthritis, Rheumatoid/drug therapy
- Arthritis, Rheumatoid/immunology
- Arthritis, Rheumatoid/pathology
- B-Lymphocytes/immunology
- B-Lymphocytes/metabolism
- B-Lymphocytes/pathology
- Drug Administration Schedule
- Humans
- Iodine Radioisotopes/adverse effects
- Isotope Labeling/methods
- Positron-Emission Tomography/methods
- Rituximab
- Thyroid Gland/drug effects
- Tissue Distribution
- Treatment Outcome
- Whole Body Imaging
Collapse
|
72
|
McGuinnes C, Duffin R, Brown S, L. Mills N, Megson IL, MacNee W, Johnston S, Lu SL, Tran L, Li R, Wang X, Newby DE, Donaldson K. Surface Derivatization State of Polystyrene Latex Nanoparticles Determines both Their Potency and Their Mechanism of Causing Human Platelet Aggregation In Vitro. Toxicol Sci 2010; 119:359-68. [DOI: 10.1093/toxsci/kfq349] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
|
73
|
Tran L, Baars JW, Aarden L, Beijnen JH, Huitema ADR. Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. Hum Antibodies 2010; 19:7-13. [PMID: 20555126 DOI: 10.3233/hab-2010-0215] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
BACKGROUND In this study, we investigated the pharmacokinetics of rituximab in patients with CD20 positive non-Hodgkin lymphoma, to get more insight into the factors that influence the pharmacokinetics of rituximab. This may aid to understand variability of treatment outcome, in patients with a CD20 positive malignancy treated with rituximab. METHODS In this study, patients with a CD20 positive B-cell malignancy who were treated with rituximab containing regimens were included. Induction treatment schedules consisted of a combination of rituximab with chemotherapy for 4-8 cycles. Maintenance treatment consisted of a 2 or 3-monthly dose of 375 mg/m2 rituximab intravenously for 2 years. On the day of the treatment with rituximab, preinfusion blood samples were taken. Also, after the end of treatment, selected blood samples were taken. Rituximab levels were measured with a validated enzyme-linked immunosorbent assay (ELISA). An antigen binding assay was applied for determination of human-antibodies against chimeric-antibodies (HACAs). RESULTS Eight patients were on induction therapy. Rituximab levels of one patient on induction therapy remained very low after the first course. This patient had a chronic lymphoid leukemia with circulating tumor cells and a high tumor burden. Apart from one patient with mantle cell lymphoma, all patients on induction therapy had a complete response. Five patients were on maintenance therapy. Trough levels of 4 patients on three-monthly schedule maintenance therapy remained constant, with a median concentration of 6 mu g/mL (range 0.5-11.7 microg/mL). One patient had a relapse during his maintenance treatment. The elimination half-life at steady state of rituximab in all patients was estimated to be 19.2 (+/- 15.2%) days with a between-subject variability of 54%, indicating wide variability. Possible pharmacokinetic-pharmacodynamic relationship was observed as rituximab levels of the non-responders remained low compared to the rituximab levels of the responders. For all patients, concentration of HACAs remained below the quantification limit. SUMMARY/CONCLUSION Considerable inter-individual variability of rituximab levels was observed. Although the patient population was small, the results support the need for more research into the pharmacokinetics and factors that might influence the pharmacokinetic-pharmacodynamic relationships of rituximab in patients with non-Hodgkin lymphoma.
Collapse
|
74
|
Tran L, Wang B, Kompa A, Krum H. The Effect of Soluble Epoxide Hydrolase Inhibiton on Rat Cardiac Cells and Aorta in Response to Urotensin II. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
75
|
Wang B, Jin H, Tran L, O’Loughlan M, Ho P, Shen Y, Xu G, Krum H, Li C. Bioactive Compounds Isolated from Salvia miltiorrhiza Exert Anti-hypertrophic Anti-fibrotic and Cardiac Protective Effects Via Reactive Oxygen Species Pathway. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|